Cure8 research brief
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at risk helps patients and clinicians plan monitoring and supportive care.
Patients with Crohn’s disease or ulcerative colitis, clinicians who manage biologic therapy, researchers studying treatment outcomes, and patients currently on or considering biologic drugs.
This retrospective cohort study used a large multi-institutional electronic health record database (TriNetX) to compare surgical rates after initiation of biologic therapy in two eras (2004–2014 vs 2014–2024).
After propensity matching, the authors report a lower proportion of patients undergoing surgery in the contemporary biologic era (5.9%) versus the earlier era (8.4%), with a relative reduction of ~29.8%. Crohn’s disease patients and those with nutritional compromise remained more likely to require surgery despite biologic exposure.
The study treats surgical intervention after biologic start as a surrogate for treatment failure and focuses on operative procedures as the endpoint.
Because it is retrospective and based on de-identified EHR data, there may be residual confounding, differences in coding, and limited granular clinical details (disease severity, exact biologic agents, adherence, perioperative factors).
The findings suggest that modern biologic therapy is associated with reduced but still significant surgical burden, especially for Crohn’s disease. If you’re tracking IBD treatments and outcomes, this paper highlights that surgery remains relevant for a subset of patients and that nutritional status is an important factor to monitor and address.
This is a retrospective observational analysis of de-identified EHR data (TriNetX) and uses surgery after biologic initiation as a proxy for treatment failure. Such studies can show associations but cannot prove causation; detailed clinical factors and reasons for surgery may be incompletely captured.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...
Understanding which patients are at higher risk for serious complications after IBD surgery can help patients and clinicians weigh risks, plan preoperative optimization, and guide research into preventive strategies.
People with IBD often take biologics and may need or want implant-based breast surgery.
